Literature DB >> 2866227

Cytotoxic lymphocytes in the lungs of mice infected with respiratory syncytial virus.

G Taylor, E J Stott, A J Hayle.   

Abstract

Mice infected with respiratory syncytial virus (RSV) developed cytotoxic lymphocytes in the lungs, which lysed RSV-infected, but not uninfected cells. Cytotoxic activity was greatest 7 to 9 days after infection, was virus-specific, MHC-restricted and abolished by treatment of lymphocytes with anti-Thy 1.2 or with anti-Lyt 2.2 sera and complement. There was a close temporal relationship between the appearance of these cytotoxic lymphocytes in the lung and clearance of virus. In contrast, RSV persisted in the lungs of athymic (nude) mice and such animals failed to develop RSV-specific cytotoxic lymphocytes. Thus, cytotoxic T-cells may have an important role in recovery from RSV infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866227     DOI: 10.1099/0022-1317-66-12-2533

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  27 in total

Review 1.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.

Authors:  P J Openshaw; K Anderson; G W Wertz; B A Askonas
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  Flow cytometric analysis of pulmonary lymphocytes from mice infected with respiratory syncytial virus.

Authors:  P J Openshaw
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

4.  Primary cytotoxic T-cell responses to bovine respiratory syncytial virus in calves.

Authors:  R M Gaddum; R S Cook; L H Thomas; G Taylor
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

5.  Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.

Authors:  J A Nicholas; K L Rubino; M E Levely; E G Adams; P L Collins
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

6.  Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.

Authors:  E J Stott; L A Ball; K K Young; J Furze; G W Wertz
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

7.  T cell redistribution kinetics after secondary infection of BALB/c mice with respiratory syncytial virus.

Authors:  J L Kimpen; P L Ogra
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

8.  Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis.

Authors:  P S McNamara; P Ritson; A Selby; C A Hart; R L Smyth
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.